Volume 74, Issue 2 pp. 124-127

Clinical correlates of submicroscopic deletions involving the ABLBCR translocation region in chronic myeloid leukemia

Yinlee Yoong

Yinlee Yoong

Division of Hematology, Department of Internal Medicine

Search for more papers by this author
Todd J. VanDeWalker

Todd J. VanDeWalker

Laboratory of Cytogenetics, Mayo Clinic, Rochester, MN, USA

Search for more papers by this author
Richard O. Carlson

Richard O. Carlson

Laboratory of Cytogenetics, Mayo Clinic, Rochester, MN, USA

Search for more papers by this author
Gordon W. Dewald

Gordon W. Dewald

Laboratory of Cytogenetics, Mayo Clinic, Rochester, MN, USA

Search for more papers by this author
Ayalew Tefferi

Ayalew Tefferi

Division of Hematology, Department of Internal Medicine

Search for more papers by this author
First published: 11 January 2005
Citations: 22
Ayalew Tefferi MD, Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Tel: 507 284 3159
Fax: 507 266 4972
e-mail: [email protected]

Abstract

Abstract: Recent reports indicate a prognostically detrimental effect of submicroscopic ablbcr deletions associated with the break and fusion points of the derivative chromosome 9 [der(9)] in chronic myeloid leukemia (CML). In a retrospective cohort of 92 patients with CML, the incidence of an atypical D-FISH pattern, that is consistent with a der(9) deletion was 20%. Complete clinical information was available in 82 patients and revealed no significant differences between 18 deleted and 64 non-deleted cases in platelet count, circulating blast percentage, spleen size, or karyotype profile at presentation. However, der(9)-deleted patients presented with significantly lower hemoglobin levels and higher leukocyte counts. At a median follow-up of 31 months, the incidence of disease transformation, drug therapy response, and survival were similar between the two groups. These results are contrary to previous reports that suggested inferior survival as well as poor response to alpha interferon therapy in CML patients carrying der(9) deletions.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.